Dexmedetomidine preconditioning ameliorates lung injury induced by pulmonary ischemia/reperfusion by upregulating promoter histone H3K4me3 modification of KGF-2.
Adrenergic alpha-2 Receptor Agonists
/ pharmacology
Animals
Cell Membrane Permeability
Dexmedetomidine
/ pharmacology
Endothelium, Vascular
/ drug effects
Fibroblast Growth Factor 10
/ chemistry
Histones
/ chemistry
Jumonji Domain-Containing Histone Demethylases
/ genetics
Lung Injury
/ etiology
Male
Mice
Mice, Inbred C57BL
Promoter Regions, Genetic
Reperfusion Injury
/ complications
Up-Regulation
Dexmedetomidine
Endothelial barrier dysfunction
Ischemia/reperfusion
JMJD3
KGF-2
Lung injury
Journal
Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226
Informations de publication
Date de publication:
15 09 2021
15 09 2021
Historique:
received:
28
04
2021
revised:
28
07
2021
accepted:
30
07
2021
pubmed:
6
8
2021
medline:
16
11
2021
entrez:
5
8
2021
Statut:
ppublish
Résumé
Keratinocyte growth factor (KGF)-2 has been highlighted to play a significant role in maintaining the endothelial barrier integrity in lung injury induced by ischemia-reperfusion (I/R). However, the underlying mechanism remains largely unknown. The aims of this study were to determine whether dexmedetomidine preconditioning (DexP) modulates pulmonary I/R-induced lung injury through the alteration in KGF-2 expression. In our I/R-modeled mice, DexP significantly inhibited pathological injury, inflammatory response, and inflammatory cell infiltration, while promoted endothelial barrier integrity and KGF-2 promoter activity in lung tissues. Bioinformatics prediction and ChIP-seq revealed that I/R significantly diminished the level of H3K4me3 modification in the KGF-2 promoter, which was significantly reversed by DexP. Moreover, DexP inhibited the expression of histone demethylase JMJD3, which in turn promoted the expression of KGF-2. In addition, overexpression of JMJD3 weakened the protective effect of DexP on lung injury in mice with I/R. Collectively, the present results demonstrated that DexP ameliorates endothelial barrier dysfunction via the JMJD3/KGF-2 axis.
Identifiants
pubmed: 34352276
pii: S0014-4827(21)00315-3
doi: 10.1016/j.yexcr.2021.112762
pii:
doi:
Substances chimiques
Adrenergic alpha-2 Receptor Agonists
0
Fibroblast Growth Factor 10
0
Histones
0
histone H3 trimethyl Lys4
0
Dexmedetomidine
67VB76HONO
Jumonji Domain-Containing Histone Demethylases
EC 1.14.11.-
Kdm6b protein, mouse
EC 1.5.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
112762Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.